Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on April 22, 2022. The filing details the entry into a Material Definitive Agreement involving a Registered Direct Offering and a concurrent Private Placement of warrants.
Key Financial Metrics and Transaction Details
- Common Stock Sold: 9,339,436 shares at $0.25 per share.
- Warrants Issued: 7,004,578 unregistered warrants (75% of shares sold) with an exercise price of $0.3399 per share.
- Warrant Terms: Exercisable six months after issuance; expire five and one-half years from issuance.
- Gross Proceeds: Approximately $2.3 million (before fees and expenses).
- Placement Agent Fees: 8.0% of gross proceeds plus $75,000 for expenses.
- Use of Proceeds: General corporate purposes, working capital, and advancing the preclinical and clinical pipeline.
Material Changes and Operational Impacts
- Suspension of ATM Program: The Company suspended its "At the Market" (ATM) Offering Agreement dated February 5, 2021, which allowed for the sale of up to $25 million of common stock.
- Voting Agreements: Investors participating in the offering entered into voting agreements to vote all beneficially owned shares (including those purchased) at the next stockholders' meeting, though they are not required to vote for or against specific proposals.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance or updated clinical milestones beyond the general statement that proceeds will advance the pipeline. The document includes standard risk disclosures regarding the representations and warranties in the Purchase Agreement, noting they are for risk allocation between parties and may not reflect materiality standards viewed by stockholders. The warrants were sold unregistered under Section 4(a)(2) and Rule 506 exemptions.
Investor Verification Checklist
- Verify the dilution impact of the 9,339,436 new shares and 7,004,578 warrants on existing shareholders.
- Confirm the exact net proceeds after deducting the 8.0% placement fee and $75,000 expense reimbursement.
- Review the full text of the Voting Agreements (Exhibit 10.2) to understand any potential constraints on future corporate governance decisions.
- Monitor the status of the suspended ATM program to determine if or when it will be reinstated.